Regeneron Pharmaceuticals (REGN) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US75886F1075
Regeneron Pharmaceuticals financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 14.34 bn USD |
| Operating income | 3.58 bn USD |
| EBIT | 5.27 bn USD |
| Net income | 4.50 bn USD |
| Diluted EPS – continuing operations | 41.48 USD |
Full history since 1990, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
More stocks
- Christian Dior SE (CDI.PA)
- PNC Financial Services (PNC)
- Marsh McLennan (MRSH)
- Brookfield Corp (BN)
- 3M (MMM)
- Japan Tobacco Inc (2914.T)
- American Tower (AMT)
- Lloyds Banking Group PLC (LLOY.L)
- Cambricon Technologies Corp Ltd (688256.SS)
- Hewlett Packard Enterprise (HPE)
- Barclays PLC (BARC.L)
- Intuit (INTU)
Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.